Consumption of cardiovascular and antithrombotic drugs during the spread of coronavirus infection in retail sector of the Samara region pharmaceutical market
- Authors: Petrukhina I.K.1, Lebedev P.A.1, Ryazanova T.K.1, Blinkova P.R.1, Paranina E.V.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 12, No 4 (2021)
- Pages: 219-226
- Section: Original study articles
- URL: https://journals.rcsi.science/2221-7185/article/view/96365
- DOI: https://doi.org/10.17816/22217185.2021.4.201282
- ID: 96365
Cite item
Full Text
Abstract
Aim. Study of multi-year sales statistics in pharmacy market segment to assess the volume and structure of consumed cardiovascular and antithrombotic drugs under COVID-19 pandemic conditions.
Material and methods. Data on nomenclature and sales volumes of drugs in pharmacy segment of Samara region in 2015–2020.
Results. It is shown that the share of basic cardiovascular drugs in physical terms is insignificant (5.2-3%). The largest volume of sales are drugs of angiotensin-converting enzyme inhibitor group (28%) and b-adrenoblockers (23.5%). Fixed combinations of hypotensive drugs account for only 13% of the volume of sold basic cardiovascular drugs, and the share of statins is 7.6%, which does not correspond to their role as the most effective drugs in primary and secondary cardiac prevention. The share of antithrombotic drugs in total sales in volume terms was 0.45% in 2015–2019. In absolute terms, sales of anticoagulants and disaggregants increased in 2018–2020, which was accompanied by an average 15% increase in the cost per daily dose. Among disaggregants, acetylsalicylic acid (66.6%), clopidogrel (21.6%), and dipyridamole (10.2%) are most frequently sold. The share of disaggregants in sales fell from 74.8 to 57.6% at the expense of acetylsalicylic acid drugs. In 2020, consumption of dipyridamole increased significantly to 16.6% due to inclusion of the drug in protocols for managing patients with COVID-19. Among anticoagulants, the proportion of new oral medications is characterized by a progressive increase from 7.8% in 2015 to 27% in 2020. During the COVID-19 pandemic, the most demanded group of Xa factor blockers is dominated by apixaban (63.8%), which can be explained by the lower cost (by 16%) of a daily equivalent dose compared to rivaroxaban.
Conclusion. Low consumption of basic cardiovascular drugs among the population of Samara region, especially statins and combined hypotensive drugs was observed. During COVID-19 pandemic there was an increase in consumption of antithrombotic drugs, due to dipyridamole and new oral anticoagulants.
Full Text
##article.viewOnOriginalSite##About the authors
Irina K. Petrukhina
Samara State Medical University
Email: palebedev@yahoo.com
ORCID iD: 0000-0001-6207-5575
D. Sci. (Pharmaceut.), Assoc. Prof.
Russian Federation, SamaraPetr A. Lebedev
Samara State Medical University
Email: palebedev@yahoo.com
ORCID iD: 0000-0003-1404-7099
D. Sci. (Med.), Prof.
Russian Federation, SamaraTatyana K. Ryazanova
Samara State Medical University
Email: palebedev@yahoo.com
ORCID iD: 0000-0002-4581-8610
Cand. Sci. (Med.), Cand. Sci. (Pharmaceut.)
Russian Federation, SamaraPolina R. Blinkova
Samara State Medical University
Email: palebedev@yahoo.com
ORCID iD: 0000-0002-8604-0729
Graduate Student
Russian Federation, SamaraElena V. Paranina
Samara State Medical University
Author for correspondence.
Email: palebedev@yahoo.com
ORCID iD: 0000-0001-7021-4061
Cand. Sci. (Med.)
Russian Federation, SamaraReferences
- Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6):2001227. doi: 10.1183/13993003.01227-2020
- Potere N, Valeriani E, Candeloro M, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020;24(1):389. doi: 10.1186/s13054-020-03022-1
- Болевич C.Б., Болевич С.С. Комплексный механизм развития СOVID-19. Сеченовский вестник. 2020;11(2):50-61 [Bolevich SB, Bolevich SS. Complex mechanism of COVID-19 development. Sechenov Medical Journal. 2020;11(2):50-61 (in Russian)]. doi: 10.47093/2218-7332.2020.11.2.50-61
- Responding to noncommunicable diseases during and beyond the COVID-19 pandemic. Jeneva 2020 (WHO/2019-nCoV/Noncommunicable_diseases/Policy_brief/2020).
- Monaco A, Blanco AC, Cobain M, et al. The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID 19 pandemic. Aging Clin Exp Res. 2021;33:2899-907. doi: 10.1007/s40520-021-01922-y
- Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015;1(117):59-66 [Leonova MV, Steinberg LL, Belousov YuB, et al. Results of pharmacoepidemiologic study of arterial hypertension Pifagor IV: Physicians compliance. Russian Journal of Cardiology. 2015;(1):59-66 (in Russian)]. doi: 10.15829/1560-4071-2015-1-59-66
- Фармацевтический рынок России 2020. Режим доступа: https://dsm.ru/docs/analytics/2020_Report_rus.pdf. Ссылка активна на 05.12.2021 [Pharmaceutical Market in Russia 2020. Available at: https://dsm.ru/docs/analytics/2020_Report_rus.pdf. Accessed: 05.12.2021 (in Russian)].
- The top 300 drugs of 2021 provided by the ClinCalc drugstats Database. Available at: https://clincalc.com/DrugStats/Top300Drugs.aspx. Accessed: 05.12.2021.
- Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. J Am Soc Hypertens. 2018;12(8):579.e1-73. doi: 10.1016/j.jash.2018.06.010
- Бурашникова И.С., Цветов В.М., Мирзаев К.Б., Сычев Д.А. Возможность и перспективы применения препарата дипиридамол у пациентов с COVID-19. Качественная клиническая практика. 2020;4S:92-5 [Burashnikova IS, Tsvetov VM, Mirzaev KB, Sychev DA. Current and future use of dipyridamole in patients with COVID-19. Good Clinical Practice. 2020;4S:92-5 (in Russian)]. doi: 10.37489/2588-0519-2020-S4-92-95
- Куртов И.В., Берман Ю.О., Никулина Н.А. Возможность неспецифической первичной профилактики новой коронавирусной инфекции COVID-19 у медицинских работников с применением дипиридамола. Тромбоз, гемостаз и реология. 2020;4 [Kurtov IV, Berman YO, Nikulina NA, et al. The opportunity of dipyridamole using for nonspecific primary prophylaxis against the COVID-19 infection in healthcare staff. Tromboz, gemostaz i reologiya. 2020;4 (in Russian)]. doi: 10.25555/THR.2020.4.0947
- Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Краткая версия. Режим доступа: https://covid19.rosminzdrav.ru/wp-content/uploads/2021/10/short_bmp_13-1.pdf. Ссылка активна на 05.12.2021 [Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Interim guidelines. Short version. Available at: https://covid19.rosminzdrav.ru/wp-content/uploads/2021/10/short_bmp_13-1.pdf. Accessed: 05.12.2021 (in Russian)].